Ipca Labs FY26 Net Profit Rises 55%; Projects 12-13% Revenue Growth for FY27

2 min read Updated on 02 Jun 2026, 09:17 AM

Reviewed by

Naman SScanX News Team

AI Summary

Ipca Laboratories reported a 55% surge in FY26 consolidated net profit to ₹1,141.12 crore, with revenue rising 8% to ₹9,646.33 crore and EBITDA margins improving to 20.72%. For FY27, the company projects 12-13% consolidated revenue growth, EBITDA margins of 22-22.3%, and domestic branded business growth of ~12%, while Unichem's US business is expected to grow ~10% with overall margins of 12-13%.

*this image is generated using AI for illustrative purposes only.

Ipca Laboratories Limited reported a 55% increase in consolidated net profit to ₹1,141.12 crore for the financial year ended March 31, 2026, driven by strong operational performance and growth across key segments. The company's board has recommended a dividend of ₹6 per share (600%) for the fiscal year, subject to shareholder approval at the ensuing Annual General Meeting. Looking ahead, the company has projected consolidated revenue growth of about 12% to 13% for FY27, with EBITDA margins expected to rise to around 22% to 22.3% from the current 20.7%.

Consolidated Financial Performance

For FY26, the company recorded consolidated revenue from operations of ₹9,646.33 crore, an 8% increase from ₹8,939.59 crore in the previous year. Profit before tax for the year stood at ₹1,572.52 crore, compared to ₹1,131.14 crore in FY25. The consolidated EBITDA margin improved to 20.72% from 18.94% in the prior year. In Q4 FY26, consolidated revenue grew 6% year-on-year to ₹2,388.48 crore, while net profit for the quarter rose to ₹299.07 crore.

Metric	FY26 (₹ Crore)	FY25 (₹ Crore)
Consolidated Revenue	9,646.33	8,939.59
Profit Before Tax	1,572.52	1,131.14
Net Profit	1,141.12	737.68
EBITDA Margin	20.72%	18.94%

Standalone Results and Segment Growth

On a standalone basis, net profit for FY26 increased 74% to ₹1,132.52 crore, with revenue from operations rising 10% to ₹7,336.75 crore. The company reported robust growth in its formulations business, with domestic formulations income up 10% to ₹3,817.24 crore and export income up 11% to ₹3,129.43 crore. The Active Pharmaceutical Ingredients (APIs) segment also recorded a 10% revenue growth during the year.

FY27 Outlook and Business Projections

Ipca Laboratories has projected consolidated revenue growth of about 12% to 13% for FY27, with EBITDA margins anticipated to rise to around 22% to 22.3% from the current 20.7%. The domestic branded business anticipates growth of around 12% for FY27, driven by 1% to 2% from new products and the remainder from price increases and volume. The company's annual price increases are typically 5% to 6%, but this year may be higher at 6% to 7% to counter rising input costs.

Regarding its Unichem subsidiary, the US business is expected to rise by about 10% this financial year, with overall margins anticipated at 12% to 13% for FY27.

Projection	FY27 Guidance
Consolidated Revenue Growth	~12% to 13%
EBITDA Margin	~22% to 22.3%
Domestic Branded Business Growth	~12%
Growth from New Products	1% to 2%
Annual Price Increase	6% to 7%
Unichem US Business Growth	~10%
Unichem Overall Margins	12% to 13%

Dividend Declaration

The Board of Directors has recommended a dividend of ₹6 per equity share of ₹1 each (600%) for the financial year ended March 31, 2026. The company has fixed Friday, August 7, 2026, as the record date for determining shareholder entitlement to the dividend, pending approval at the Annual General Meeting.

Auditor's Report

The statutory auditors, N V C & Associates LLP, have issued an unmodified opinion on the audited standalone and consolidated financial results for the year ended March 31, 2026. The results were reviewed by the Audit Committee and approved by the Board on May 29, 2026.

Historical Stock Returns for IPCA Laboratories